Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
      Google Scholar   
Citation:
J Clin Oncol vol 40 (5) 449-58
Year:
2022
Type:
Manuscript
Funding:
AFT
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
11
Parents:
3470  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
Pfizer  
Grants:
 
Corr. Author:
 
Authors:
                                                                   
Networks:
LAPS-CT018, LAPS-MA036, LAPS-MN026, LAPS-NY016, LAPS-PA015, LAPS-TN008   
Study
AFT-05
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: